TABLE 1.
Baseline demographic and clinical characteristics
| APP (n = 82) | PP (n = 81) | |
|---|---|---|
| Age, median (range), year | 61.0 (32–77) | 61.0 (33–80) |
| Age group | ||
| <65 years | 57 (69.5) | 55 (67.9) |
| ≥65 years | 25 (30.5) | 26 (32.1) |
| Sex | ||
| Male | 60 (73.2) | 59 (72.8) |
| Female | 22 (26.8) | 22 (27.2) |
| Race | ||
| Asian | 82 (100) | 81 (100) |
| Tobacco use history | ||
| Never | 30 (36.6) | 27 (33.3) |
| Current or former | 52 (63.4) | 54 (66.7) |
| ECOG PS | ||
| 0 | 22 (26.8) | 22 (27.2) |
| 1 | 60 (73.2) | 59 (72.8) |
| Liver metastasis | ||
| Yes | 12 (14.6) | 5 (6.2) |
| No | 70 (85.4) | 76 (93.8) |
| Intended no. of chemotherapy cycles at induction | ||
| 4 | 53 (64.6) | 50 (61.7) |
| 6 | 29 (35.4) | 31 (38.3) |
| Non‐squamous histology detail | ||
| n | 82 | 80 |
| Adenocarcinoma | 76 (92.7) | 78 (97.5) |
| Adenocarcinoma with neuroendocrine features | 3 (3.7) | 0 |
| Adenosquamous | 0 | 2 (2.5) |
| Not applicable | 3 (3.7) | 0 |
| EML4‐ALK rearrangement status | ||
| Negative | 82 (100) | 81 (100) |
| EGFR mutation status | ||
| Positive a | 1 (1.2) | 5 (6.2) |
| Negative | 81 (98.8) | 76 (93.8) |
| KRAS mutation status | ||
| Positive | 2 (2.4) | 3 (3.7) |
| Negative | 34 (41.5) | 32 (39.5) |
| Unknown | 46 (56.1) | 46 (56.8) |
Note: Data are n (%) except where otherwise indicated. Data cutoff was July 18, 2019.
Abbreviations: APP, atezolizumab plus cisplatin plus pemetrexed; ECOG PS, Eastern Cooperative Oncology Group performance status; PP, cisplatin plus pemetrexed.
a
All 6 patients had tumors harboring non‐sensitizing EGFR exon 20 insertion mutations.